Use of cannabinoids in the treatment of epilepsy
US11154516B2 · kind B2 · utility
38Cited by
27References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2020 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Dec 11, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.